health
PHERGain reports five-year outcomes of chemotherapy de-escalation in HER2-positive breast cancer
In the phase 2 PHERGain trial, a PET- and pathology-guided strategy had an estimated five-year invasive disease-free survival of 89.5% among patients assigned to the adaptive-treatment group who underwent surgery. Exploratory ctDNA analyses linked early clearance with higher pathological complete response rates and better five-year outcomes.